Top Markets
#1 DogBull DogBull +108.89%
#2 Siacoin Siacoin +62.61%
#3 MarsCoin MarsCoin +56.44%
#4 ADO Protocol ADO Protocol +52.97%
#5 The Bitcoin Bull The Bitcoin Bull +32.78%
#6 Ontology Gas Ontology Gas +19.78%
#7 Akedo Akedo +12.83%
#8 Arowana Arowana +11.61%
#9 UnifAI Network UnifAI Network +11.46%
#10 Cash Cat Cash Cat +11.11%
Coin of the day
DogBull DogBull
Settings
Language
ENGLISH
Currency
USD
Theme
EyePoint Pharmaceuticals, Inc. EyePoint Pharmaceuticals, Inc.

EyePoint Pharmaceuticals, Inc.

EYPT
Rank in Stocks #15070
EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the... EyePoint Pharmaceuticals, Inc. is a pharmaceutical firm dedicated to the creation and marketing of ophthalmic solutions for various eye ailments. Its operations span the United States, China, and the United Kingdom. Among its commercialized product portfolio are ILUVIEN, an injectable, sustained-release micro-insert designed to treat diabetic macular edema, and YUTIQ, an intravitreal implant containing fluocinolone acetonide, which targets chronic non-infectious uveitis impacting the posterior segment of the eye. The company also offers DEXYCU, a dexamethasone intraocular suspension, utilized to manage post-operative ocular inflammation, such as that occurring after cataract surgery. Looking ahead, EyePoint is actively developing several pipeline therapies. This includes EYP-1901, a novel, bioerodible tyrosine kinase inhibitor currently formulated for twice-yearly administration, which is under development for conditions like wet age-related macular degeneration, diabetic retinopathy, and retinal vein occlusion. Additionally, YUTIQ50 is being advanced as a treatment for chronic non-infectious uveitis affecting the posterior region of the eye. To bolster its market reach and development efforts, the company maintains strategic alliances with entities such as Alimera Sciences, Inc., Bausch & Lomb, OncoSil Medical UK Limited, Ocumension Therapeutics, and Equinox Science, LLC. Furthermore, a commercial collaboration with ImprimisRx PA, Inc. specifically focuses on the joint promotion of DEXYCU for inflammation following ocular surgery. Incorporated in 1987, the organization was previously known as pSivida Corp. before officially rebranding as EyePoint Pharmaceuticals, Inc. in March 2018. Its corporate headquarters are situated in Watertown, Massachusetts.
Share Price
$4.48
Last synced: 2026-08-31
Market Cap
$375.37M
Change (1 day)
-0.06%
Change (1 year)
-61.30%
Country
US
Trade EyePoint Pharmaceuticals, Inc. (EYPT)

Category

Healthcare
Operating Margin for EyePoint Pharmaceuticals, Inc. (EYPT)
Operating Margin as of 2026 TTM: 0.00%
According to EyePoint Pharmaceuticals, Inc. latest financial reports and stock price the company's current Operating Margin (TTM) is 0.00%. At the end of 2026 the company had an Operating Margin of 0.00%.
Operating Margin history for EyePoint Pharmaceuticals, Inc. from 2026 to 2026
Operating Margin at the end of each year
Year Operating Margin Change
Not enough data for the provided dates.
Operating Margin for similar companies or competitors
Company Operating Margin Operating Margin Difference Country
Vertex Pharmaceuticals Incorporated Vertex Pharmaceuticals Incorporated
Vertex Pharmaceuticals Incorporated
VRTX.US
38.59% -
US
Argenx SE Argenx SE
Argenx SE
ARGX.US
28.81% -
NL
CSL Limited CSL Limited
CSL Limited
CSL.AX
25.57% -
AU
Moderna, Inc. Moderna, Inc.
Moderna, Inc.
MRNA.US
-149.01% -
US
Lonza Group AG Lonza Group AG
Lonza Group AG
LONN.SW
0.00% -
CH
What is a company's Operating Margin?
The operating margin is a key indicator to assess the profitability of a company. Higher operating margins are generaly better as they show that a company is able to sell its products or services for much more than their production costs. The operating margin is calculated by dividing a company's earnings by its revenue.